MacFadyen RJ , Lee AFC , Morton JJ,Pringle SD, Struthers ADHow often are AII and aldosterone concentrations raised during chronic ACI treatment in CCF. Heart1999;82:57-61.
2.
Edmond M., Mock M., David KBV, Fisher LD, Holmes DR, Chaitman BR, Kaiser GC, Alderman E., Killip III T. and CASS Participants.Long term survival of medically treated patients in the Coronary ArterySurgery Study (CASS) Registry Circulation1994;90:2645-57.
3.
Zuanetti G., De Ferrari GM, Priori SG, Schwartz PJProtective effect of vagal stimulation on reperfusion arrhythmias in cats . Circ Res1987;61(3):429-35.
4.
La Rovere MT , Bigger JT, Marcus FI, MortaraA,Sachwartz PJ for the ATRAMI Investigators .Baroreflex sensitivity and heart rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet1998;351:478-84.
5.
Zuanetti G. , Neilson JMM , Latini R., Santoro E., Maggioni AP, Ewing DJ on behalf of GISSI-2 investigators.Prognostic significance of heart rate variability in post myocardial infarction patients in the fibrinolytic era. The GISSI-2 results . Circulation1996;94:432-6.
6.
Weber K., Brilla CGPathological hypertrophy and cardiac interstitium: fibrosis and renin angiotensin aldosterone system. Circulation1991;83:1849-65.
7.
Takeda Y., Miyamori I., Yoneda T. et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab1996;81(8):2797-800.
8.
Ideka U., Kanbe T., Nakayama I., Kawahara Y., Yokoyama M., Shimada K.Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 . Eur J Pharmacol1995;290:69-73.
9.
Farquharson C., Struthers ADSpironolactone increases NO bioactivity, improves endothelial dysfunction and suppresses vascular AI/AII conversion in chronic heart failure. Circulation2000 ;101:594-7.
10.
Duprez DA, de Buyzere ML, Reitzschel ER et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J1998;19:1371-6.
11.
Brown NJ, Kin KS, ChenYQ et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab2000;85:336-44.
12.
Rocha R., Chander PN, Zuckerman A., Stier CTMineralocorticoid blockade reduces vascular injury in stroke prone hypertensive rats. Hypertension1998;31[part 2]:451-8.
13.
Harada E.,Yoshimura M.,Yasul H. et al. Aldosterone induces ACE gene expression in cultured neonatal rat cardiocytes. Circulation2001;104:137-9.
14.
Brilla CG, Matsubara LS, Weber KTAnti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronisin. J Mol Coll Cardiol1993;25:563-75.
15.
Klappacher G., Franzen P., Haab D. et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol1995;75:913-8.
16.
Diez J., Laviadfes C., Mayor G., Gil MJ, Monreal I.Increased serum concentrations of procollagen peptides in essential hypertension . Circulation1995;91:1450-6.
17.
MacFadyen RJ , Barr CS, Struthers AD .Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res1997;35:30-4.
18.
Zannad F., Alla F., Dousset B. et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with CHF. Circulation2000:102;2700-6.
19.
Pitt B., Zannad F., Remme WJ et al. The effect of spironolactone on mortality and morbidity in chronic heart failure. N Engl J Med199;341:709-17.
20.
Yee KM, Pringle SD, Struthers ADCircadian influence of aldosterone blockade on QT dispersion and heat rate variability in chronic heart failure. J Am Coll Cardiol2001; 37:1800-7.
21.
Chowdhary S. ,Townend JNRole of NO in the regulation of cardiovascular autonomic control. Clin Sci1999;97:5-17.
22.
Spiker LE, Corti R., Binggeli C. et al. Baroreceptor dysfunction induced by NO synthase inhibition in humans. J Am Coll Cardiol2000;36:213-8.
